Scarica l'app Stockscreener
18.10
1.74%
-0.32
Dopo l'orario di chiusura:
17.78
-0.32
-1.77%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
SRPT6155802 Latest News and Headlines - TradingView
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to "Hold" at Zacks Research - MarketBeat
Sarepta Therapeutics (SRPT) submits Form 13F showing one entry and $0 value - Stock Titan
Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom - Streetwise Reports
Sarepta Therapeutics (SRPT) sees 5.05% ownership reported by AQR in 13G/A - Stock Titan
Bank of America Corp DE Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
SRPT|Sarepta Therapeutics Inc|Price:17.890|Chg%:-0.530 - TradingKey
Sarepta Therapeutics, Inc. (SRPT) Stock Forecasts - Yahoo Finance
Sarepta (SRPT) Q2 2026 Earnings Call Transcript - AOL.com
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
Assenagon Asset Management S.A. Makes New $8.16 Million Investment in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits
Dimensional Fund Advisors LP Sells 121,412 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - The National Law Review
Sarepta Therapeutics, Inc. (SRPT) Investor Outlook: Analyzing The 31.63% Potential Upside - DirectorsTalk Interviews
Why Sarepta Therapeutics (SRPT) Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO - Sahm
Sarepta Therapeutics, Inc. Revenue Breakdown – BX:AB3A - TradingView
Price to earnings forward of Sarepta Therapeutics, Inc. – BX:AB3A - TradingView
Sarepta Therapeutics (SRPT) Brings In Michael Severino As Chief Executive Officer - Sahm
Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
(SRPT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
State Street (NYSE: STT) discloses 8.4% Sarepta Therapeutics ownership via Schedule 13G - Stock Titan
Traders Purchase Large Volume of Call Options on Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT) - The Globe and Mail
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated - TradingView
Oppenheimer Adjusts PT on Sarepta Therapeutics to $35 From $37, Maintains Outperform Rating - marketscreener.com
Sarepta Therapeutics Navigates FDA Hold on Elevidys in Expanding DMD Market - Streetwise Reports
Empowered Funds LLC Has $2.48 Million Stake in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics Q2 Earnings Call Highlights - MarketBeat
Is Sarepta Therapeutics Inc (SRPT) a Value Opportunity After Q2 Loss? GF Score: 63/100, Revenue at $401.3M - GuruFocus
Sarepta Therapeutics Inc (SRPT) (Q2 2026) Earnings Call Highligh - GuruFocus
Sarepta Therapeutics Inc (SRPT) (Q2 2026) Earnings Call Highlights: Strong Profitability and ... - Yahoo Finance
Sarepta Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:SRPT) 2026-08-06 - Seeking Alpha
BlackRock, Inc. Adds to Sarepta Therapeutics Inc (SRPT) -- Shares Look 88% Undervalued on GF Value - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Releases Quarterly Earnings Results, Beats Estimates By $0.42 EPS - marketbeat.com
Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call transcript: Sarepta beats Q2 2026 estimates as shares rise after hours - Investing.com
Sarepta rises on quarterly double-line beat - Seeking Alpha
Sarepta Therapeutics: Q2 Earnings Snapshot - barchart.com
Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Posts Q2 Adjusted EPS $0.64 per Share - marketscreener.com
Sarepta Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Reports Q2 Revenue $401.3M, vs. FactSet Est of $366.4M - marketscreener.com
Sarepta Therapeutics Inc. R (AB3A.F) Q2 FY2026 earnings call transcript - Yahoo Finance
Sarepta Therapeutics 2Q 2026: Revenue $328.7M, EPS $(0.05) — 10-Q Summary - TradingView
Sarepta Therapeutics, Inc. Revises Revenue Guidance for the Year 2026 - marketscreener.com
Sarepta Therapeutics (NASDAQ: SRPT) swings to Q2 loss, details ELEVIDYS - Stock Titan
Sarepta Therapeutics Inc expected to post earnings of 26 cents a shareEarnings Preview - TradingView
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a 49% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Sarepta Therapeutics (SRPT) Names A New CEO, Is The Stock Cheap? - Yahoo Finance
Vanguard Portfolio Management (SRPT) discloses 8.05% beneficial stake in Sarepta - Stock Titan
BlackRock (NYSE: BLK) discloses 16.6M-share Sarepta Therapeutics (SRPT) position in 13G/A - Stock Titan
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
ADAR1 Capital Management LLC Has $5.70 Million Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Leadership changes afoot at two CGT biotechs - Yahoo Finance
H.C. Wainwright reiterates Sarepta stock Sell rating on CEO transition By Investing.com - Investing.com Canada
Sarepta names Michael Severino, former Tessera CEO, as new chief executive - STAT
SRPT Looks 87.5% Undervalued on GF Value™ - GuruFocus
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):